Core Insights - The 17th China Bio-Industry Conference was held on September 4, 2025, in Wuhan, showcasing the latest innovations in the bio-manufacturing sector [1][3] - The conference highlighted the achievements of Wuhan's Optics Valley Bio-City, which has become a leading hub for biopharmaceuticals in China, housing over 4,200 companies and nurturing 531 high-tech enterprises [3][6] Group 1: Event Highlights - The conference released the "Most Innovative Bio-Manufacturing Base" list, recognizing ten national bio-industry bases, including Wuhan, Shanghai, Beijing, Hangzhou, and Shenzhen [1] - Five companies from Wuhan, including He Yuan Bio, Aibotai, and Youzhiyou, were ranked among the top 20 most innovative enterprises from hundreds of projects across 23 national bio-industry bases [1] Group 2: Achievements in Bio-Medicine - In the first half of the year, Optics Valley Bio-City approved 14 new class I innovative drugs for clinical trials, the highest number in three years, and 28 class III medical devices, matching last year's total [4] - The city is currently developing over 400 class I new drugs, accounting for 90% of the province's total, and has certified over 307 class III medical devices, representing 70% of the province's total [4] Group 3: Notable Exhibits - Major companies from Optics Valley Bio-City showcased groundbreaking products at the conference, including the world's first 5.0T whole-body MRI system and a novel "rice-derived" recombinant human albumin injection [4] - Binhui Bio's OH2 injection, the first oncolytic virus drug using type II herpes simplex virus as a carrier, is undergoing critical clinical research and has received national support for major new drug development [4]
武汉等10城市国家生物产业基地获评最具创新力基地